I Haberl
- Co-authors
- Michael HejnaH. HuberAndrea GsurJohannes DrachNiklas ZojerMarkus RadererSaili ZhaoG Hamilton
- Topics
- Drug Transport and Resistance Mechanisms (4 papers)Cancer, Hypoxia, and Metabolism (3 papers)Peptidase Inhibition and Analysis (3 papers)
- Partner nations
- AustriaSwitzerlandCanada
In The Last Decade
I Haberl
18 papers receiving 499 citations
Peers
Comparison fields: 5 of 84
- Oncology 220
- Molecular Biology 142
- Epidemiology 76
- Immunology 67
- Surgery 65
Countries citing papers authored by I Haberl
This map shows the geographic impact of I Haberl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I Haberl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I Haberl more than expected).
Fields of papers citing papers by I Haberl
This network shows the impact of papers produced by I Haberl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I Haberl. The network helps show where I Haberl may publish in the future.
Co-authorship network of co-authors of I Haberl
This figure shows the co-authorship network connecting the top 25 collaborators of I Haberl. A scholar is included among the top collaborators of I Haberl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I Haberl. I Haberl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 8 | |
| 3 | 14 | |
| 4 | 19 | |
| 5 | 9 | |
| 6 | Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract. | 19 |
| 7 | 14 | |
| 8 | 50 | |
| 9 | 15 | |
| 10 | 72 | |
| 11 | 7 | |
| 12 | Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3. | 5 |
| 13 | 11 | |
| 14 | 46 | |
| 15 | 13 | |
| 16 | 194 | |
| 17 | 2 | |
| 18 | In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells. | 14 |
About I Haberl
I Haberl is a scholar working on Oncology, Sensory Systems and Cancer Research, having authored 18 papers that have together received 513 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Oncology (220 citations), Transplantation (15 citations) and Pharmaceutical Science (31 citations). I Haberl has collaborated with scholars based in Austria, Switzerland and Canada. Frequent co-authors include Michael Hejna, H. Huber, Andrea Gsur, Johannes Drach, Niklas Zojer, Markus Raderer, Saili Zhao, G Hamilton, Michael Andreeff and Markus Raderer. Their work appears in journals such as Blood, Cancer and Journal of Controlled Release.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.